ACRS250117C5000
- 0.15
- 0.000.00%
Aclaris Therapeutics Newsroom
Aclaris Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.
Aclaris Therapeutics Analyst Ratings
H.C. Wainwright Upgrades Aclaris Therapeutics(ACRS.US) to Buy Rating, Announces Target Price $20
Jefferies Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $7
Aclaris Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy Rating
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Raises Target Price to $5
Stifel Nicolaus Remains a Hold on Aclaris Therapeutics (ACRS)
Cantor Fitzgerald Upgrades Aclaris Therapeutics(ACRS.US) to Buy Rating
Aclaris Therapeutics Raised to Outperform From Market Perform by Leerink Partners
A Quick Look at Today's Ratings for Aclaris Therapeutics(ACRS.US), With a Forecast Between $3 to $13
BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics: Hold Rating Amid Mixed Trial Outcomes and Strategic Uncertainties
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), McKesson (MCK) and Enhabit, Inc (EHAB)
Stifel Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating, Raises Target Price to $3
Stifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)
BTIG Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
Aclaris Therapeutics Analyst Ratings
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating